Loading...
Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
Emicizumab is a bispecific, humanized, monoclonal antibody mimicking the factor (F) VIII cofactor activity in mediating the generation of FXa by FIXa in patients with hemophilia A (HA). This subcutaneous non-factor agent has been recently extensively approved for the prophylaxis of patients of HA pa...
Na minha lista:
| Udgivet i: | Drug Des Devel Ther |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007498/ https://ncbi.nlm.nih.gov/pubmed/32099331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S167731 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|